Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Defence Therapeutics Secures NOL From Health Canada For Phase I Trial of AccuTOX
Defence Therapeutics获得加拿大卫生部的NOL,用于AccuTOX的I期临床试验。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册